OncoMatch/Clinical Trials/NCT07106736
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Is NCT07106736 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BCMA CAR-T and GPRC5D/CD3 BiTEs for multiple myeloma, newly diagnosed.
Treatment: BCMA CAR-T · GPRC5D/CD3 BiTEs — This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly diagnosed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) positive (positive)
Tumor cells were BCMA positive
Required: GPRC5D positive (positive)
Tumor cells were GPRC5D positive
Performance status
ECOG 3–4(Completely disabled)
ECOG performance status 3-4
Prior therapy
Cannot have received: bcma-targeted therapy
Cannot have received: car-t cell therapy
Lab requirements
Kidney function
creatinine clearance ≥ 30ml/min (cockroft-gault formula)
Liver function
serum total bilirubin <2 x uln, serum ast and alt <3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify